CINTICHEM TECHNETIUM 99M HEDSPA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CINTICHEM TECHNETIUM 99M HEDSPA (CINTICHEM TECHNETIUM 99M HEDSPA).
Technetium-99m medronic acid (HEDSPA) is a diagnostic radiopharmaceutical that localizes in bone by chemisorption to hydroxyapatite crystals, allowing imaging of areas of increased osteogenic activity.
| Metabolism | Not metabolized; eliminated primarily by renal excretion as unchanged drug. |
| Excretion | Primarily renal; 85-90% of injected dose eliminated in urine within 24 hours. |
| Half-life | Terminal elimination half-life is approximately 2-3 hours for the 99mTc complex, reflecting rapid renal clearance; clinically, imaging is performed 2-4 hours post-injection. |
| Protein binding | Approximately 25-30% bound to plasma proteins, primarily albumin and globulins. |
| Volume of Distribution | Approximately 0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid and bone matrix. |
| Bioavailability | Intravenous administration only; bioavailability 100%. |
| Onset of Action | Bone uptake detectable within 30 minutes; optimal imaging at 2-4 hours after intravenous injection. |
| Duration of Action | Bone localization persists for several hours, but imaging window is typically 2-4 hours; by 24 hours, most activity is excreted. |
370-740 MBq (10-20 mCi) intravenously as a single dose for bone imaging.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment guidelines; use with caution in severe renal impairment (GFR <30 mL/min) as elimination may be delayed. |
| Liver impairment | No dose adjustment required for hepatic impairment; not significantly hepatically metabolized. |
| Pediatric use | Weight-based: 7.4-11.1 MBq/kg (0.2-0.3 mCi/kg) intravenously; minimum dose 37 MBq (1 mCi). |
| Geriatric use | No specific dose adjustment; use standard adult dosing, but consider age-related decline in renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CINTICHEM TECHNETIUM 99M HEDSPA (CINTICHEM TECHNETIUM 99M HEDSPA).
| Breastfeeding | Technetium-99m is excreted in human breast milk; M/P ratio not established. Temporary cessation of breastfeeding for at least 24-48 hours post-administration recommended to minimize infant exposure. |
| Teratogenic Risk | Insufficient human data; animal studies not conducted. Radiation exposure from Technetium-99m may carry risk of fetal harm, especially during organogenesis (weeks 2-7). Theoretical risk of teratogenicity increases with cumulative dose; recommended to avoid use during pregnancy unless benefit clearly outweighs risk. |
■ FDA Black Box Warning
No FDA black box warnings.
| Serious Effects |
["Known hypersensitivity to medronic acid or any component of the formulation"]
| Precautions | ["Risk of allergic reactions including anaphylaxis","Radiopharmaceuticals should be used with caution in pregnant and lactating women","Ensure adequate hydration to reduce radiation dose to bladder","Not for intrathecal use"] |
| Food/Dietary | No specific food interactions. However, maintain adequate hydration and avoid diuretic substances (e.g., caffeine, alcohol) as they may alter hydration status and affect image quality. |
| Clinical Pearls |
Loading safety data…
| Fetal Monitoring |
| No specific monitoring required beyond standard radiation safety precautions. Ensure adequate hydration to facilitate excretion. For inadvertent exposure, consult radiation safety officer; consider fetal dose estimation. |
| Fertility Effects | No known adverse effects on fertility from diagnostic doses of Technetium-99m HEDSPA. High cumulative radiation doses may theoretically affect gonadal function; minimal risk with standard imaging. |
| Technetium-99m medronate (HEDSPA) is a bone imaging agent. Ensure adequate hydration before and after administration to enhance renal clearance and reduce radiation burden. Optimal imaging occurs 2-4 hours post-injection. Accumulation in bone is proportional to osteoblastic activity and blood flow. Note artifacts from urinary contamination; have patient void before imaging. Use with caution in renal impairment as delayed soft tissue clearance may degrade image quality. |
| Patient Advice | This is a radioactive diagnostic agent used for bone scans. · Drink plenty of fluids before and after the injection to help clear the material from your body. · You will need to empty your bladder frequently and just before the scan to avoid image interference. · There are no significant food restrictions; however, avoid caffeine or diuretics that may cause dehydration. · Tell your doctor if you are pregnant, breastfeeding, or have kidney problems. · The scan will be performed a few hours after injection; follow instructions for imaging timing. |